|
JP2020180136A
|
|
Methods and compositions for treatment of melanoma
|
|
WO2020232141A2
|
|
Compositions and methods for treating t cell exhaustion
|
|
WO2020210231A1
|
|
Compositions and methods for the cry opreservation of immune cells
|
|
WO2020106710A1
|
|
Veterinary device for adoptive cell therapy
|
|
AU2018308982A1
|
|
Methods and compositions for the treatment of cancer
|
|
AU2017367730A1
|
|
Nanoparticle formulations
|
|
US2018036396A1
|
|
Methods and compositions for the treatment of melanoma
|
|
SG11202000612TA
|
|
Methods and compositions for the treatment of melanoma
|
|
AU2015205879A1
|
|
Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
|
|
CA2879667A1
|
|
Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
|
|
US2014255369A1
|
|
Production and use of red blood cells
|
|
US2014273212A1
|
|
Expansion of adult stem cells in vitro
|
|
AU2012216462A1
|
|
Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
|
|
CN104353066A
|
|
Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
|
|
CA2731767A1
|
|
Differentiated anucleated cells and method for preparing the same
|
|
SG190661A1
|
|
Antibodies and processes for preparing the same
|
|
CA2699312A1
|
|
Compounds for treating abnormal cellular proliferation
|
